4.74
0.08 (1.72%)
| 前收盘价格 | 4.66 |
| 收盘价格 | 4.67 |
| 成交量 | 1,150,359 |
| 平均成交量 (3个月) | 1,402,577 |
| 市值 | 616,120,576 |
| 价格/销量 (P/S) | 2.90 |
| 股市价格/股市净资产 (P/B) | 1.88 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2026 |
| 营业毛利率 | -5.71% |
| 营业利益率 (TTM) | -36.12% |
| 稀释每股收益 (EPS TTM) | -0.090 |
| 季度收入增长率 (YOY) | -7.60% |
| 季度盈利增长率 (YOY) | 75.20% |
| 总债务/股东权益 (D/E MRQ) | 4.19% |
| 流动比率 (MRQ) | 5.62 |
| 营业现金流 (OCF TTM) | 21.30 M |
| 杠杆自由现金流 (LFCF TTM) | 30.18 M |
| 资产报酬率 (ROA TTM) | -3.51% |
| 股东权益报酬率 (ROE TTM) | -2.91% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Cytek Biosciences, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.17 |
|
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 9.15% |
| 机构持股比例 | 62.13% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合